Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01389661Phase 1Completed

Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)

Role: collaborator

NCT02440074Phase 1Withdrawn

Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)

Role: collaborator

NCT01183728Phase 1Completed

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells

Role: collaborator

NCT01562002Phase 1Completed

Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome

Role: collaborator

All 4 trials loaded